• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

前列腺癌淋巴结转移灶的雄激素受体状态

Androgen receptor status of lymph node metastases from prostate cancer.

作者信息

Hobisch A, Culig Z, Radmayr C, Bartsch G, Klocker H, Hittmair A

机构信息

Department of Urology, University of Innsbruck, Austria.

出版信息

Prostate. 1996 Feb;28(2):129-35. doi: 10.1002/(SICI)1097-0045(199602)28:2<129::AID-PROS9>3.0.CO;2-B.

DOI:10.1002/(SICI)1097-0045(199602)28:2<129::AID-PROS9>3.0.CO;2-B
PMID:8604394
Abstract

To date androgen receptor (AR) expression and structure in human prostatic cancer have been studied in primary tumor specimens and in cell lines. Investigation of alterations in the androgen-signalling transduction cascade in prostatic carcinoma metastases is important to improve our understanding of tumor progression towards androgen insensitivity. In the present study we have collected data comparing AR expression in both the primary tumors and the respective pelvic lymph node metastases. Formalin-fixed and paraffin-embedded tissues derived from the primary tumors and positive lymph nodes of 12 patients undergoing radical prostatectomy were immunostained for the AR and prostate-specific antigen (PSA). AR expression was evaluated with the polyclonal antibody PG-21, which is directed against amino acid 1-21 in the N-terminal region of the AR. All primary tumors stained for the AR. In 8 of the 12 lymph nodes examined more than 50% of the tumor cells were AR positive and displayed a uniform staining pattern; in one lymph node metastasis remarkable heterogeneity in AR expression was observed. In two cases less than 10% of the tumor cells stained for the AR. In one case the lymph node metastasis was immunohistochemically negative for the AR, whereas the primary tumor obtained from the same patient displayed intense staining for the AR. PSA was expressed in all metastases and primary tumors. Our data demonstrate that loss of the AR in lymph node metastases from prostatic carcinoma is a rare event.

摘要

迄今为止,已在原发性肿瘤标本和细胞系中研究了人前列腺癌中雄激素受体(AR)的表达和结构。研究前列腺癌转移灶中雄激素信号转导级联的改变,对于增进我们对肿瘤向雄激素不敏感进展的理解很重要。在本研究中,我们收集了比较原发性肿瘤和相应盆腔淋巴结转移灶中AR表达的数据。对12例行根治性前列腺切除术患者的原发性肿瘤和阳性淋巴结的福尔马林固定石蜡包埋组织进行AR和前列腺特异性抗原(PSA)免疫染色。用针对AR N端区域第1-21位氨基酸的多克隆抗体PG-21评估AR表达。所有原发性肿瘤均对AR染色呈阳性。在检查的12个淋巴结中的8个中,超过50%的肿瘤细胞AR呈阳性,并显示出均匀的染色模式;在一个淋巴结转移灶中,观察到AR表达存在明显异质性。在2例中,不到10%的肿瘤细胞对AR染色呈阳性。在1例中,淋巴结转移灶免疫组化检测AR呈阴性,而同一患者的原发性肿瘤对AR染色呈强阳性。PSA在所有转移灶和原发性肿瘤中均有表达。我们的数据表明,前列腺癌淋巴结转移灶中AR缺失是罕见事件。

相似文献

1
Androgen receptor status of lymph node metastases from prostate cancer.前列腺癌淋巴结转移灶的雄激素受体状态
Prostate. 1996 Feb;28(2):129-35. doi: 10.1002/(SICI)1097-0045(199602)28:2<129::AID-PROS9>3.0.CO;2-B.
2
Androgen receptor expression in prostate cancer lymph node metastases is predictive of outcome after surgery.雄激素受体在前列腺癌淋巴结转移中的表达可预测手术后的预后。
J Urol. 1999 Apr;161(4):1233-7.
3
The loss of 5alpha-reductase type I and type II mRNA expression in metastatic prostate cancer to bone and lymph node metastasis.在发生骨转移和淋巴结转移的转移性前列腺癌中I型和II型5α-还原酶信使核糖核酸表达缺失。
Clin Cancer Res. 2003 May;9(5):1815-9.
4
Distant metastases from prostatic carcinoma express androgen receptor protein.前列腺癌的远处转移灶表达雄激素受体蛋白。
Cancer Res. 1995 Jul 15;55(14):3068-72.
5
Transforming growth factor-beta 1: comparative immunohistochemical localization in human primary and metastatic prostate cancer.转化生长因子-β1:在人原发性和转移性前列腺癌中的比较免疫组织化学定位
Lab Invest. 1995 Nov;73(5):628-35.
6
The role of P501S and PSA in the diagnosis of metastatic adenocarcinoma of the prostate.P501S和前列腺特异性抗原(PSA)在前列腺转移性腺癌诊断中的作用。
Am J Surg Pathol. 2007 Sep;31(9):1351-5. doi: 10.1097/PAS.0b013e3180536678.
7
Comparison of proliferating cell nuclear antigen immunostaining in lymph node metastases and primary prostate adenocarcinoma after neoadjuvant androgen deprivation therapy.新辅助雄激素剥夺治疗后淋巴结转移灶与原发性前列腺腺癌中增殖细胞核抗原免疫染色的比较。
Scand J Urol Nephrol. 2004;38(1):19-25. doi: 10.1080/00365590310006345.
8
Loss of p53 and c-myc overrepresentation in stage T(2-3)N(1-3)M(0) prostate cancer are potential markers for cancer progression.在T(2 - 3)N(1 - 3)M(0)期前列腺癌中,p53缺失和c - myc过度表达是癌症进展的潜在标志物。
Mod Pathol. 2002 Jan;15(1):35-44. doi: 10.1038/modpathol.3880487.
9
Androgen receptor expression in clinically localized prostate cancer: immunohistochemistry study and literature review.临床局限性前列腺癌中雄激素受体的表达:免疫组织化学研究及文献综述
Asian J Androl. 2008 Nov;10(6):855-63. doi: 10.1111/j.1745-7262.2008.00428.x.
10
Prediction of pelvic lymph node metastasis by the ratio of cathepsin B to stefin A in patients with prostate carcinoma.组织蛋白酶B与丝抑素A的比值对前列腺癌患者盆腔淋巴结转移的预测作用
Cancer. 2002 Jun 15;94(12):3141-9. doi: 10.1002/cncr.10604.

引用本文的文献

1
Induction of promyelocytic leukemia zinc finger protein by miR-200c-3p restores sensitivity to anti-androgen therapy in androgen-refractory prostate cancer and inhibits the cancer progression via down-regulation of integrin α3β4.miR-200c-3p 通过诱导早幼粒细胞白血病锌指蛋白恢复去势抵抗性前列腺癌对雄激素治疗的敏感性,并通过下调整合素 α3β4 抑制肿瘤进展。
Cell Oncol (Dordr). 2023 Aug;46(4):1113-1126. doi: 10.1007/s13402-023-00803-y. Epub 2023 Mar 30.
2
Selective targeting of the androgen receptor-DNA binding domain by the novel antiandrogen SBF-1 and inhibition of the growth of prostate cancer cells.新型抗雄激素 SBF-1 对雄激素受体-DNA 结合域的选择性靶向作用及其对前列腺癌细胞生长的抑制作用。
Invest New Drugs. 2021 Apr;39(2):442-457. doi: 10.1007/s10637-020-01050-w. Epub 2021 Jan 7.
3
Recent Discoveries in the Androgen Receptor Pathway in Castration-Resistant Prostate Cancer.去势抵抗性前列腺癌雄激素受体通路的最新发现
Front Oncol. 2020 Oct 8;10:581515. doi: 10.3389/fonc.2020.581515. eCollection 2020.
4
Development and prevalence of castration-resistant prostate cancer subtypes.去势抵抗性前列腺癌亚型的发展和流行。
Neoplasia. 2020 Nov;22(11):566-575. doi: 10.1016/j.neo.2020.09.002. Epub 2020 Sep 25.
5
Secondary Resistant Mutations to Small Molecule Inhibitors in Cancer Cells.癌细胞中对小分子抑制剂的继发性耐药突变
Cancers (Basel). 2020 Apr 9;12(4):927. doi: 10.3390/cancers12040927.
6
Supraphysiological androgens suppress prostate cancer growth through androgen receptor-mediated DNA damage.超生理雄激素通过雄激素受体介导的 DNA 损伤抑制前列腺癌生长。
J Clin Invest. 2019 Jul 16;129(10):4245-4260. doi: 10.1172/JCI127613.
7
Prognostic Significance of High Androgen Receptor Expression in Prostatic Acinar Adenocarcinoma.雄激素受体高表达在前列腺腺泡腺癌中的预后意义
Asian Pac J Cancer Prev. 2019 Mar 26;20(3):893-896. doi: 10.31557/APJCP.2019.20.3.893.
8
Endothelial cells promote metastasis of prostate cancer by enhancing autophagy.内皮细胞通过增强自噬促进前列腺癌转移。
J Exp Clin Cancer Res. 2018 Sep 10;37(1):221. doi: 10.1186/s13046-018-0884-2.
9
Inhibiting Multiple Deubiquitinases to Reduce Androgen Receptor Expression in Prostate Cancer Cells.抑制多种去泛素化酶以降低前列腺癌细胞中的雄激素受体表达。
Sci Rep. 2018 Sep 3;8(1):13146. doi: 10.1038/s41598-018-31567-3.
10
Correlation between Fusion Protein and Androgen Receptor Expression by Immunohistochemistry in Prostate, Possible Role in Diagnosis and Therapy.融合蛋白与雄激素受体在前列腺中的免疫组化表达相关性及其在诊断和治疗中的可能作用
J Cancer. 2017 Aug 5;8(13):2604-2613. doi: 10.7150/jca.16751. eCollection 2017.